🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 hora
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/09/2021 | 188,47 | 190,60 | 188,42 | 188,86 | +0,24% | 1,16% | 1.599.100 |
| 14/09/2021 | 190,86 | 191,75 | 188,21 | 188,41 | -1,21% | 1,85% | 960.700 |
| 13/09/2021 | 190,07 | 193,25 | 189,61 | 190,72 | +1,14% | 1,92% | 972.700 |
| 10/09/2021 | 188,17 | 190,15 | 186,15 | 188,57 | +0,26% | 2,13% | 1.375.500 |
| 09/09/2021 | 189,42 | 190,20 | 188,05 | 188,09 | -1,71% | 1,14% | 1.449.900 |
| 08/09/2021 | 191,81 | 193,40 | 191,06 | 191,37 | -0,43% | 1,22% | 940.300 |
| 07/09/2021 | 196,20 | 197,05 | 192,00 | 192,20 | -2,95% | 2,57% | 1.714.000 |
| 03/09/2021 | 198,50 | 199,18 | 196,66 | 198,05 | -0,59% | 1,27% | 985.400 |
| 02/09/2021 | 198,06 | 199,80 | 196,60 | 199,22 | +1,06% | 1,62% | 1.240.100 |
| 01/09/2021 | 200,62 | 202,55 | 196,35 | 197,14 | -1,57% | 3,09% | 1.450.700 |
| 31/08/2021 | 200,21 | 200,35 | 198,15 | 200,29 | +0,40% | 1,10% | 1.889.700 |
| 30/08/2021 | 199,30 | 201,56 | 198,70 | 199,49 | -0,22% | 1,44% | 1.119.600 |
| 27/08/2021 | 198,15 | 202,77 | 195,85 | 199,92 | +0,84% | 3,49% | 1.290.000 |
| 26/08/2021 | 200,94 | 202,74 | 197,91 | 198,25 | -1,53% | 2,40% | 1.134.700 |
| 25/08/2021 | 199,59 | 202,17 | 198,09 | 201,33 | +0,80% | 2,04% | 1.192.700 |
| 24/08/2021 | 198,82 | 200,16 | 196,68 | 199,73 | +0,67% | 1,75% | 880.100 |
| 23/08/2021 | 197,27 | 200,50 | 196,14 | 198,40 | +1,30% | 2,21% | 1.125.800 |
| 20/08/2021 | 195,60 | 198,61 | 194,30 | 195,85 | +0,42% | 2,20% | 974.700 |
| 19/08/2021 | 194,30 | 197,92 | 194,30 | 195,04 | +0,14% | 1,86% | 1.140.900 |
| 18/08/2021 | 198,72 | 198,72 | 194,68 | 194,77 | -1,85% | 2,03% | 1.120.200 |
| 17/08/2021 | 189,47 | 198,59 | 188,84 | 198,44 | +3,91% | 5,15% | 2.082.200 |
| 16/08/2021 | 194,67 | 194,95 | 189,61 | 190,97 | -1,74% | 2,74% | 3.548.900 |
| 13/08/2021 | 195,00 | 195,71 | 193,70 | 194,36 | -0,23% | 1,03% | 3.231.900 |
| 12/08/2021 | 195,72 | 196,35 | 193,88 | 194,81 | -0,23% | 1,26% | 3.580.200 |
| 11/08/2021 | 196,82 | 199,28 | 194,53 | 195,25 | -0,62% | 2,41% | 4.204.300 |
| 10/08/2021 | 200,50 | 200,66 | 195,34 | 196,46 | -1,97% | 2,65% | 2.891.700 |
| 09/08/2021 | 201,38 | 201,54 | 198,63 | 200,40 | -0,13% | 1,45% | 2.314.400 |
| 06/08/2021 | 202,99 | 204,00 | 200,53 | 200,67 | -1,14% | 1,71% | 1.542.200 |
| 05/08/2021 | 200,26 | 203,13 | 199,73 | 202,99 | +1,70% | 1,70% | 1.975.500 |
| 04/08/2021 | 200,00 | 202,00 | 199,11 | 199,59 | -0,23% | 1,44% | 2.612.200 |